Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	PIK-93	3	72	sigmoid	sigmoid	BT20 PIK-93 0 3 72	8	2.532	2.65	0.419	0.097	7.54	-1.0	1.05	0.982	5.47e-06	NA	2.5	0.42	0.892	2.5	0.0	1.17	0.971	2.45e-05	NA
BT-20	ZSTK474	3	72	sigmoid	sigmoid	BT20 ZSTK474 0 3 72	8	2.609	0.457	-0.00222	0.296	0.783	-0.31	0.895	0.982	5.76e-06	NA	0.422	0.163	0.702	0.422	0.0	0.82	0.971	2.52e-05	NA
HCC70	Dactolisib	3	72	sigmoid	sigmoid	HCC70 dactolisib 0 3 72	8	2.430	0.738	0.321	0.312	18.6	-0.818	0.3	0.975	1.64e-05	NA	0.688	0.365	0.675	0.635	0.0134	0.338	0.97	2.7e-05	NA
HCC1806	Trametinib	1	72	sigmoid	sigmoid	HCC1806 trametinib 0 1 72	8	2.751	Inf	0.795	0.139	0.00972	0.802	0.873	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC1806	Trametinib	3	72	sigmoid	sigmoid	HCC1806 trametinib 0 3 72	8	3.204	Inf	0.822	0.12	0.00981	0.829	0.872	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC70	CAL-101	1	72	sigmoid	sigmoid	HCC70 idelalisib 0 1 72	8	1.384	2.78	0.485	0.0894	0.883	0.424	1.65	0.972	2.11e-05	NA	Inf	0.662	0.941	0.846	0.626	1.66	0.97	2.79e-05	NA
HCC1806	Trametinib	2	72	sigmoid	sigmoid	HCC1806 trametinib 0 2 72	8	2.836	Inf	0.8	0.135	0.00973	0.808	0.873	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC70	Torin2	2	72	sigmoid	sigmoid	HCC70 Torin2 0 2 72	8	1.826	0.0342	-0.522	0.671	0.401	-1.0	0.446	0.979	9.23e-06	NA	0.0639	0.0733	0.507	0.0639	0.0	0.462	0.969	2.98e-05	NA
HCC38	MK2206	2	72	sigmoid	sigmoid	HCC38 MK-2206 0 2 72	8	2.159	Inf	0.788	0.0476	0.776	0.775	1.99	0.972	2.1e-05	NA	Inf	0.785	0.951	0.752	0.772	1.98	0.969	2.9e-05	NA
BT-20	Omipalisib	2	72	sigmoid	sigmoid	BT20 omipalisib 0 2 72	8	1.717	0.00324	-0.799	1.1	0.00361	-0.354	4.99	0.808	0.00704	NA	0.00518	0.0194	0.291	0.00429	0.111	1.34	0.968	3.16e-05	NA
Hs 578T	Dactolisib	3		sigmoid	sigmoid	Hs578T dactolisib 3	8	2.837	0.0118	0.0569	0.624	0.00848	0.115	0.799	0.96	6.53e-05	NA	0.00728	0.164	0.377	0.0043	0.212	1.05	0.968	3.34e-05	NA
HCC70	Trametinib	1	72	sigmoid	sigmoid	HCC70 trametinib 0 1 72	8	1.421	0.015	0.339	0.521	0.00411	0.34	0.879	0.966	4.1e-05	NA	Inf	0.566	0.653	0.00373	0.566	0.875	0.968	3.23e-05	NA
BT-549	Buparlisib	3	72	sigmoid	sigmoid	BT549 buparlisib 0 3 72	8	1.795	0.602	-0.351	0.295	1.64	-1.0	1.09	0.983	4.52e-06	NA	0.804	0.132	0.777	0.804	0.0	1.26	0.968	3.41e-05	NA
Hs 578T	MK2206	3		sigmoid	sigmoid	Hs578T MK-2206 3	8	2.883	Inf	0.737	0.0965	0.144	0.768	1.94	0.962	5.58e-05	NA	Inf	0.666	0.873	0.135	0.7	1.85	0.967	3.69e-05	NA
HCC38	AS605240	1	72	sigmoid	sigmoid	HCC38 AS-605240 0 1 72	8	1.744	Inf	0.734	0.0803	0.448	0.691	0.881	0.969	2.92e-05	NA	Inf	0.78	0.932	0.405	0.748	0.895	0.967	3.48e-05	NA
HCC70	TGX221	3	72	sigmoid	sigmoid	HCC70 TGX-221 0 3 72	8	2.459	Inf	0.7	0.0886	0.338	0.675	1.11	0.971	2.48e-05	NA	Inf	0.671	0.9	0.295	0.648	1.13	0.966	3.94e-05	NA
HCC70	MK2206	2	72	sigmoid	sigmoid	HCC70 MK-2206 0 2 72	8	1.690	0.446	0.244	0.2	0.301	0.226	1.53	0.973	1.92e-05	NA	1.03	0.448	0.851	0.266	0.44	1.56	0.965	4.11e-05	NA
BT-20	PI103	1	72	sigmoid	sigmoid	BT20 PI-103 0 1 72	8	1.924	0.646	-0.0114	0.16	0.659	-0.0268	2.6	0.978	1.1e-05	NA	0.753	0.258	0.883	0.579	0.252	2.68	0.964	4.79e-05	NA
Hs 578T	KIN001-244	1		sigmoid	sigmoid	Hs578T KIN001-244 1	8	2.041	24.7	0.739	0.0391	4.05	0.414	0.972	0.968	3.4e-05	NA	Inf	0.752	0.962	3.15	0.51	0.99	0.964	4.65e-05	NA
BT-20	Trametinib	3	72	sigmoid	sigmoid	BT20 trametinib 0 3 72	8	2.539	Inf	0.64	0.208	0.104	0.541	0.392	0.967	3.69e-05	NA	Inf	0.604	0.761	0.0656	0.513	0.391	0.964	4.56e-05	NA
HCC70	Pictilisib	2	72	sigmoid	sigmoid	HCC70 pictilisib 0 2 72	8	1.783	0.811	0.124	0.189	0.858	-0.0372	1.27	0.973	2.08e-05	NA	1.25	0.358	0.852	0.678	0.278	1.32	0.963	5.09e-05	NA
HCC70	Dactolisib	1	72	sigmoid	sigmoid	HCC70 dactolisib 0 1 72	8	1.400	0.0808	-0.0667	0.501	3.34	-1.0	0.295	0.963	5.02e-05	NA	0.753	0.344	0.673	0.753	0.0	0.308	0.962	5.37e-05	NA
HCC38	Trametinib	3	72	sigmoid	sigmoid	HCC38 trametinib 0 3 72	8	1.486	0.229	0.132	0.342	0.19	0.108	1.3	0.969	2.85e-05	NA	0.689	0.429	0.766	0.176	0.409	1.25	0.962	5.31e-05	NA
HCC70	AS605240	1	72	sigmoid	sigmoid	HCC70 AS-605240 0 1 72	8	1.387	10.4	0.487	0.159	0.247	0.497	1.34	0.963	5.14e-05	NA	Inf	0.663	0.894	0.23	0.672	1.39	0.961	6.01e-05	NA
BT-20	PI103	2	72	sigmoid	sigmoid	BT20 PI-103 0 2 72	8	1.725	0.235	-0.21	0.388	0.289	-0.212	1.7	0.975	1.64e-05	NA	0.319	0.202	0.721	0.239	0.205	1.81	0.961	5.88e-05	NA

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)